Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.

Asian Pacific journal of cancer prevention : APJCP - 1 Mar 2024

Sood Nidhi, Hamide Abdoul, Dubashi Biswajit, Nisha Yadav, Mathaiyan Jayanthi, Munirajan A K, Ganesn Prasanth, Kayal Smita

Abstract excerpt

BACKGROUND: Multiple myeloma (MM), being the second most common hematological malignancy, has garnered significant attention. The ubiquitin proteasomal pathway (UPP), crucial for normal cell function, plays a pivotal role in myeloma pathophysiology, especially with the advent of bortezomib (BTZ). Dysregulation of the UPP has implications ranging from developmental abnormalities to cancer. OBJECTIVES: This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 38546066
DOI: 10.31557/APJCP.2024.25.3.829
PMCID: PMC11152374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.PMID 38546066Read ↗

Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Semantic proximity Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Genetic factors influencing the risk of multiple myeloma bone disease.Semantic proximity Read ↗

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.Semantic proximity Read ↗

Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis.Semantic proximity Read ↗

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.Semantic proximity Read ↗

Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma.Semantic proximity Read ↗

Deciphering the genetics and mechanisms of predisposition to multiple myeloma.Semantic proximity Read ↗

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimensSemantic proximity Read ↗

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Semantic proximity Read ↗

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.